India, Sept. 8 -- India's branded pharmaceutical market saw Eli Lilly's Mounjaro cement its position as the top-selling brand in August 2026, with monthly sales value approaching Rs 100 crore, according to the latest report from Pharmarack Technologies.

Mounjaro retained the No. 1 rank both on a MAT (Moving Annual Total) and monthly basis, with August sales value of Rs 112 crore and MTH value growth of 34.1 per cent. GSK's Augmentin (Rs 94 crore) and USV's Glycomet GP (Rs 85 crore) held on to the No. 2 and No. 3 positions respectively, at both the MAT and monthly level, underscoring their consistent, established demand base even as growth rates moderate compared to newer high-momentum brands.

Commenting on the trend, Sheetal Sapale, Vic...